Acesion Pharma announces positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint achieved

Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (“AF”), the most common cardiac arrhythmia, today announced positive data from its Phase 2 trial of AP30663, a first-in-class SK ion channel inhibitor for conversion of AF to normal sinus rhythm. The trial ...

Related Keywords

Denmark ,Copenhagen ,Køavn ,John Camm ,Anders Gaarsdal Holst ,Acesion Pharma ,George University Of London ,Novo Holdings ,Atrial Fibrillation ,Gaarsdal Holst ,Chief Executive Officer ,Emeritus Professor ,Clinical Cardiology ,